Comparative Pharmacology
Head-to-head clinical analysis: CARISOPRODOL COMPOUND versus OZOBAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARISOPRODOL COMPOUND versus OZOBAX.
CARISOPRODOL COMPOUND vs OZOBAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carisoprodol is a centrally acting muscle relaxant that acts as a prodrug for meprobamate, a barbiturate-like compound with sedative and anxiolytic properties. Its mechanism is thought to involve GABA-A receptor modulation and depression of polysynaptic reflexes in the spinal cord and reticular formation. Aspirin provides analgesic and anti-inflammatory effects via irreversible inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia by mimicking endogenous endorphins.
OZOBAX (carisoprodol) is a centrally acting skeletal muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is thought to be related to its sedative properties and its metabolite, meprobamate, which has anxiolytic and sedative effects. Carisoprodol acts as a GABA-A receptor agonist and may also inhibit interneuronal activity in the spinal cord and reticular formation.
1-2 tablets (carisoprodol 200 mg/aspirin 325 mg) orally 4 times daily.
OZOBAX (baclofen) oral: Initial 5 mg three times daily, may increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg four times daily). Intrathecal: Test dose 50-100 mcg, then continuous infusion via pump 22-900 mcg/day.
None Documented
None Documented
Carisoprodol has a terminal elimination half-life of approximately 1.5–2 hours; its active metabolite meprobamate has a half-life of 9–12 hours, which may lead to prolonged effects with chronic use.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function. This supports twice-daily dosing in most patients.
Carisoprodol is primarily metabolized in the liver, with about 50% excreted renally as unchanged drug and metabolites; the major metabolite meprobamate is also renally excreted. Fecal excretion is negligible (<2%).
Primarily renal excretion of unchanged drug (approximately 70-80% of the dose) with minor biliary/fecal elimination (10-15%).
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant